AA
KROS icon

AlphaCentric Advisors’s Keros Therapeutics KROS Stock Holding History

AlphaCentric Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,000
Closed -$465K – 255
2024
Q3 		$465K Buy
+8,000
New +$395K 0.35% 78

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

AlphaCentric Advisors's KROS Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 8,000 shares — an estimated $465K sold.

AlphaCentric Advisors first reported a position in KROS in Q3 2024 and held it in 1 quarter. The position peaked at $465K in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 8,000 Keros Therapeutics shares in Q4 2024, an estimated $465K.
  • AlphaCentric Advisors first reported a position in Keros Therapeutics in Q3 2024 and held it in 1 quarter.
  • AlphaCentric Advisors's Keros Therapeutics position peaked at $465K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.